Takeda Considers Research Facility in India (India)
This article was originally published in PharmAsia News
Executive Summary
Japan's largest drug maker, Takeda, is expected to emulate fellow drug makers Daiichi Sankyo and Esai in locating research facilities in India to take advantage of lower costs. Takeda is said to be hunting for someone familiar with India to head a new division in the country. Daiichi opened an India operation in 2007 and Esai created Esai Pharmaceuticals India subsidiary. Takeda is expected to reach a final decision this year and start off with one or two products. (Click here for more
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.